Gupta, Smita <br/><br/>
Immunotherapies in diabetes mellitus type 1.  [electronic resource] 

 -  The Medical clinics of North America  May 2012 
 - 621-34, xi p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1557-9859 
<br/><br/><label>Standard No.: </label>10.1016/j.mcna.2012.04.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antilymphocyte Serum--therapeutic use<br/>Azathioprine--therapeutic use<br/>Basiliximab<br/>Chaperonin 60--therapeutic use<br/>Cyclosporine--therapeutic use<br/>Daclizumab<br/>Diabetes Mellitus, Type 1--immunology<br/>Diet<br/>Etanercept<br/>Exenatide<br/>Fatty Acids, Unsaturated--therapeutic use<br/>Glutamate Decarboxylase--therapeutic use<br/>Humans<br/>Hypoglycemic Agents--immunology<br/>Immunoconjugates--therapeutic use<br/>Immunoglobulin G--therapeutic use<br/>Immunosuppressive Agents--therapeutic use<br/>Insulin--immunology<br/>Interferon-alpha--therapeutic use<br/>Interleukin 1 Receptor Antagonist Protein--therapeutic use<br/>Islets of Langerhans Transplantation<br/>Niacinamide--therapeutic use<br/>Peptide Fragments--therapeutic use<br/>Peptides--therapeutic use<br/>Primary Prevention<br/>Pyrazines--therapeutic use<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Rituximab<br/>Secondary Prevention<br/>Sitagliptin Phosphate<br/>Tertiary Prevention<br/>Triazoles--therapeutic use<br/>Venoms--therapeutic use<br/>Vitamin D--therapeutic use<br/>Vitamins--therapeutic use